K. Hastings

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Kenneth Hastings, K L Hastings, K Hastings, K. L. Hastings, Kenneth L. Hastings, Kenneth L Hastings, K. Hastings, Ken Hastings
Publication record
97 papers · 2,386 citations · H-index 21

PAPERS

The Minipig in Biomedical Research
202586 citationsauthor #3
Risks and Benefits of Vaccine or Nonvaccine Therapeutic Interventions for COVID-19
20210 citationsauthor #1
Beyond Metabolism: Role of the Immune System in Hepatic Toxicity
202020 citationsauthor #1
Predictivity/Translatability of Toxicities Observed in Nonclinical Toxicology Studies to Clinical Safety Outcomes in Drug Development: Case Examples
20193 citationsauthor #4
Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic.
2018205 citationsauthor #9
Immunotoxicology: A Brief History.
20182 citationsauthor #1
Nonclinical safety assessment
20172 citationsauthor #2
Toxicology Testing of Drug Combinations Does Not Add Significant Value to Human Risk Evaluation Beyond What is Known for the Individual Agents
20170 citationsauthor #1
FutureTox II: in vitro data and in silico models for predictive toxicology.
2015114 citationsauthor #8
Phospholipidosis: Histologic finding or histopathology?
20141 citationsauthor #1
ICH S8: History and Perspectives
20131 citationsauthor #1
Food and Drug Administration: Nonclinical Program and Pharmaceutical Approval
20130 citationsauthor #2
Nonclinical safety assessment : a guide to international pharmaceutical regulations
20132 citationsauthor #2
Workshop Proceedings
201344 citationsauthor #6
Challenges and Opportunities in Evaluating Protein Allergenicity Across
20130 citationsauthor #6
ICH: History and Nonclinical Guidances
20131 citationsauthor #2
Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial
201219 citationsauthor #7
Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial
201217 citationsauthor #7
New Horizons and Perspectives
20110 citationsauthor #4
The Progress in Understanding the Toxicological Significance of Drug-Induced Phospholipidosis
20110 citationsauthor #4
Stress in Experiments: Stress Issues in Porcine Research
20111 citationsauthor #4
Regulatory Perspective and Use of the Minipig in Developing Marketed Products
20110 citationsauthor #4
Safety Assessment in the Minipig—Principal Body Systems
20112 citationsauthor #4
A Comparative Assessment of the Pig, Mouse and Human Genomes: Structural and Functional Analysis of Genes Involved in Immunity and Inammation
201124 citationsauthor #4
Minipigs in Absorption, Distribution, Metabolism, and Excretion (ADME) Studies: Cornelia Preuße and Mette Tingleff Skaanild
20116 citationsauthor #4
The minipig in biomedical research
20118 citationsauthor #4
Origin and Management of the Minipig
20112 citationsauthor #4
Welfare and Experimental Usage of the Minipig
20110 citationsauthor #4
Pharmacology and ADME Studies in the Minipig
20111 citationsauthor #4
Genetics and Immunology
20110 citationsauthor #4
Regulatory Issues in Preclinical Safety Studies (U.S. FDA)
20100 citationsauthor #1
Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugs
200912 citationsauthor #5
Hepatotoxicity in Oncology Drug Development
20080 citationsauthor #2
Development of a Phospholipidosis Database and Predictive Quantitative Structure-Activity Relationship (QSAR) Models
200850 citationsauthor #6
Current Regulatory Expectations for Immunotoxicology Evaluation of Pharmaceuticals
20081 citationsauthor #1
Immunotoxicology Specialty Section Annual report: 2007-2008
20080 citationsauthor #7
Acknowledgement of contributions of Dr. Harihara Mehendale as editor-in-chief of International Journal of Toxicology.
20080 citationsauthor #1
What’s So Special about the Developing Immune System?
200879 citationsauthor #2
Nonclinical Safety Assessment of Biologic Therapeutics: What We Have Learned Since ICH S6
20072 citationsauthor #1
Biological stress response terminology: Integrating the concepts of adaptive response and preconditioning stress within a hormetic dose-response framework.
2007717 citationsauthor #19
Drug-induced phospholipidosis: issues and future directions
2006214 citationsauthor #2
Risk Assessment in Drug Development: Autoimmunity
20061 citationsauthor #1
Immunotoxicity Hazard Identifi cation and Testing Guidelines
20060 citationsauthor #1
Immunotoxicity Hazard Identification and Testing Guidelines
20060 citationsauthor #1
The use of hepatotoxic signals to predict the safety of peroxisome proliferator-activated receptor agonists
20061 citationsauthor #1
Nonclinical Safety Testing of Pharmaceuticals
20062 citationsauthor #2
Clinical relevance of preclinical testing for allergic side effects.
200525 citationsauthor #3
Evaluation of a Lymph Node Proliferation Assay for its Ability to Detect Pharmaceuticals with Potential to Cause Immune-Mediated Drug Reactions
200534 citationsauthor #10
Drug allergy
20050 citationsauthor #1
Developmental toxicology evaluations--issues with including neurotoxicology and immunotoxicology assessments in reproductive toxicology studies.
200541 citationsauthor #3
Development of the ICH Guidelines for Immunotoxicology Evaluation of Pharmaceuticals Using a Survey of Industry Practices
200515 citationsauthor #7
Immunotoxicology Specialty Section Newsletter
20050 citationsauthor #2
Prospects for Developmental Immunotoxicity Guidance and an Update on ICH S8
20052 citationsauthor #1
Commentary on Hormetic Dose-Response Relationships in Immunology: Occurrence, Quantitative Features of the Dose Response, Mechanistic Foundations, and Clinical Implications
20051 citationsauthor #1
Investigative Immunotoxicology Edited by Helen Tryphonas, Michel Fournier, Barry R. Blakely, Judit E. G. Smits, and Pauline Brousseau. Taylor & Francis Inc., 2005. ISBN: 0415308542. 458 pages. Price: $149.95
20050 citationsauthor #1
Opinion in Immunotoxicology Multidimensional Immunomodulation
20041 citationsauthor #2
A proposed testing framework for developmental immunotoxicology (DIT).
200477 citationsauthor #3
Multidimensional Immunomodulation
20042 citationsauthor #2
Detection of systemic hypersensitivity to drugs using standard guinea pig assays.
200339 citationsauthor #6
Recommended Tissue List for Histopathologic Examination
20033 citationsauthor #3
Drug metabolites in safety testing.
2003130 citationsauthor #1
Implications of the new FDA/CDER immunotoxicology guidance for drugs.
200236 citationsauthor #1
Assessment of the Immunotoxic Potential of Human Pharmaceuticals: A Workshop Report
200226 citationsauthor #5
Pre-clinical methods for detecting the hypersensitivity potential of pharmaceuticals: regulatory considerations.
200113 citationsauthor #1
Immunotoxicology Evaluation of New Drugs
20010 citationsauthor #2
Drug allergy: Hazard identification and regulatory aspects
20000 citationsauthor #1
Safety evaluation of immunomodulatory biopharmaceuticals: can we improve the predictive value of preclinical studies?
20004 citationsauthor #14
Assessment of immunosuppressant drug carcinogenicity: standard and alternative animal models
20007 citationsauthor #1
Inhibition of Tumor Necrosis Factor Alpha Alters Resistance to Mycobacterium avium Complex Infection in Mice
199820 citationsauthor #2
Assessment of the skin sensitization potential of topical medicaments using the local lymph node assay: an interlaboratory evaluation.
199894 citationsauthor #11
S10/L4 - What are the perspectives for regulation in immunotoxicology?
19980 citationsauthor #1
What are the prospects for regulation in immunotoxicology?
19986 citationsauthor #1
Safety Evaluation and Risk Assessment Using Immunotoxicology Methods
19981 citationsauthor #6
Immunotoxicity of Pharmaceuticals: Current Knowledge, Testing Strategies, Risk Evaluation & Consequences for Human Health
199710 citationsauthor #5
Considerations in Assessing the Immunotoxic Potential of Investigational Drugs
19975 citationsauthor #1
Autoimmunity and Allergy: Regulatory Implications
19960 citationsauthor #1
Regulatory Issues of Importance to Developing Anti-HIV Therapeutics
19962 citationsauthor #1
Evaluation of Preclinical Findings for 10-Day IND Safety Reports: FDA Considerations
19960 citationsauthor #1
Halogenated anesthetics form liver adducts and antigens that cross-react with halothane-induced antibodies.
199521 citationsauthor #4
Trifluoroacetylation potentiates the humoral immune response to halothane in the guinea pig.
19958 citationsauthor #1
Use of staphylococcal enterotoxin A-induced lymphoproliferation and interleukin 2 production as indicators of immunotoxicity.
199410 citationsauthor #2
Immunogenicity studies of a synthetic antigen of alpha methyl dopa.
19933 citationsauthor #3
Formation and identification of protein adducts to cytosolic proteins in guinea pig liver slices exposed to halothane.
199218 citationsauthor #2
S-ethylthiotrifluoroacetate enhancement of the immune response to halothane in the guinea pig.
19911 citationsauthor #1
Screening for antibodies associated with halothane hepatitis.
19919 citationsauthor #1
Covalent binding of a halothane metabolite and neoantigen production in guinea pig liver slices.
19914 citationsauthor #2
Generation and detection of neoantigens in guinea pig liver slices incubated with halothane.
19919 citationsauthor #2
A350 PRODUCTION AND DETECTION OF VOLATILE ANESTHETIC-ASSOCIATED NEOANTIGENS IN VITRO
19900 citationsauthor #2
A359 THE EFFECT OF VOLATILE ANESTHETICS ON ALBUMIN SYNTHESIS AND SECRETION IN THE GUINEA PIG LIVER SLICES
19900 citationsauthor #3
Glycoprotein processing inhibitors affect myogenin gene expression
19900 citationsauthor #2
Changes in the expression of the preproenkephalin a gene in the atria and the ventricles of cardiomyopathic hamsters
19890 citationsauthor #2
Production and characterization of aflatoxin B2 oximinoacetate
19899 citationsauthor #1
LABORATORY METHODS FOR THE DIAGNOSIS OF HALOTHANE HEPATITIS
19895 citationsauthor #1
Production and characterization of a monoclonal antibody to aflatoxin B2
198821 citationsauthor #1
Induction of ethylenediamine hypersensitivity in the guinea pig and the development of ELISA and lymphocyte blastogenesis techniques for its characterization
19871 citationsauthor #2
Induction of ethylenediamine hypersensitivity in the guinea pig and the development of ELISA and lymphocyte blastogenesis techniques for its characterization.
19875 citationsauthor #2
Immunological properties of monoclonal antibodies specific for meningococcal polysaccharides: the protective capacity of IgM antibodies specific for polysaccharide group B.
198330 citationsauthor #3

TIMELINE

1983 30 citations

1987 6 citations

1988 21 citations

1989 14 citations

1990 0 citations

1991 23 citations

1992 18 citations

1993 3 citations

1994 10 citations

1995 29 citations

1996 2 citations

1997 15 citations

1998 121 citations

2000 11 citations

2001 13 citations

2002 62 citations

2003 172 citations

2004 80 citations

2005 118 citations

2006 218 citations

2007 719 citations

2008 130 citations

2009 12 citations

2010 0 citations

2011 44 citations

2012 36 citations

2013 48 citations

2014 1 citations

2015 114 citations

2017 2 citations

2018 207 citations

2019 3 citations

2020 20 citations

2021 0 citations

2025 86 citations

K. Hastings

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT